Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)

CompletedOBSERVATIONAL
Enrollment

57

Participants

Timeline

Start Date

February 2, 2016

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Interventions
BIOLOGICAL

Recipients

"1. Adult recipient:~ * collected 20 ml pre-transplant~ * collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~ * collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~2. Children recipients~ * collected residual blood pre-transplant~ * collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~ * collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"

BIOLOGICAL

Donors

"1. Adult donors :~ * collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~ * collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~2. Children donors samples~ * collected residual blood~ * 2ml of bone marrow (bottom of tube)"

Trial Locations (1)

75015

Hopital Necker, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02194868 - Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT) | Biotech Hunter | Biotech Hunter